Molecular biology of bladder cancer

被引：27

作者：

Luis, Nuno M. ^{[1
]}

Lopez-Knowles, Elena ^{[1
]}

Real, Francisco X. ^{[1
,2
]}

机构：

[1] Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain

[2] Univ Pompeu Fabra, Barcelona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2007年 / 9卷 / 01期

关键词：

bladder; FGFR3; genetic alterations; p53; rb; urothelial carcinoma;

D O I：

10.1007/s12094-007-0003-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bladder cancer is a major cause of health expenses and it presents formidable clinical challenges. Two types of tumors have been identified, papillary and non-papillary. The former are mainly characterized by FGFR3 and chromosome 9 alterations and a low frequency of Tp53 alterations. The latter are characterized by a high frequency of alterations in genes in the p53 and Rb pathways. Chromosome 9 alterations, specially in 9q, are crucial to bladder cancer development and occur in both types of tumors. Progression of some superficial tumors ( mainly TaG3 and T1G3) to high-grade, invasive, carcinomas provides evidence of some overlap between the two pathways. Distinct gene expression profiles have been identified in superficial and invasive tumors. The stage is now ready for the clinical application of this knowledge.

引用

页码：5 / 12

页数：8

共 73 条

[1] SOX4 expression in bladder carcinoma:: Clinical aspects and in vitro functional characterization [J].

Aaboe, M ;

Birkenkamp-Demtroder, K ;

Wiuf, C ;

Sorensen, FB ;

Tbykjaer, T ;

Sauter, G ;

Jensen, KME ;

Dyrskjot, L ;

Orntoft, T .

CANCER RESEARCH, 2006, 66 (07) :3434-3442

[2] Alteration of the PATCHED locus in superficial bladder cancer [J].

Aboulkassim, TO ;

LaRue, H ;

Lemieux, P ;

Rousseau, F ;

Fradet, Y .

ONCOGENE, 2003, 22 (19) :2967-2971

[3] Human bladder tumors with 2-hit mutations of the tumor suppressor gene TSC1 and decreased expression of p27 [J].

Adachi, H ;

Igawa, M ;

Shiina, H ;

Urakami, S ;

Shigeno, K ;

Hino, O .

JOURNAL OF UROLOGY, 2003, 170 (02) :601-604

[4] Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity [J].

Adams, J ;

Cuthbert-Heavens, D ;

Bass, S ;

Knowles, MA .

CANCER LETTERS, 2005, 220 (02) :137-144

[5] Expression in bladder transitional cell carcinoma by real-time quantitative reverse transcription polymerase chain reaction array of 65 genes at the tumor suppressor locus 9q34.1-2: Identification of 5 candidates tumor suppressor genes [J].

Amira, N ;

Cancel-Tassin, G ;

Bernardin, S ;

Cochand-Priolliet, B ;

Bittard, H ;

Mangin, P ;

Fournier, G ;

Latil, A ;

Cussenot, O .

INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (04) :539-542

[6]

[Anonymous], 2004, PATHOLOGY GENETICS T

[7]

[Anonymous], BLADDER CANC

[8] Loss of FHIT expression in transitional cell carcinoma of the urinary bladder [J].

Baffa, R ;

Gomella, LG ;

Vecchione, A ;

Bassi, P ;

Mimori, K ;

Sedor, J ;

Calviello, CM ;

Gardiman, M ;

Minimo, C ;

Strup, SE ;

McCue, PA ;

Kovatich, AJ ;

Pagano, F ;

Huebner, K ;

Croce, CM .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (02) :419-424

[9] Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors [J].

Billerey, C ;

Chopin, D ;

Aubriot-Lorton, MH ;

Ricol, D ;

de Medina, SGD ;

Van Rhijn, B ;

Bralet, MP ;

Lefrere-Belda, MA ;

Lahaye, JB ;

Abbou, CC ;

Bonaventure, J ;

Zafrani, ES ;

van der Kwast, T ;

Thiery, JP ;

Radvanyi, F .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1955-1959

[10] Bladder cancer stage and outcome by array-based comparative genomic hybridization [J].

Blaveri, E ;

Brewer, JL ;

Roydasgupta, R ;

Fridlyand, J ;

DeVries, S ;

Koppie, T ;

Pejavar, S ;

Mehta, K ;

Carroll, P ;

Simko, JP ;

Waldman, FM .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :7012-7022

← 1 2 3 4 5 6 7 8 →